CapLaw-2026-42

On 11 June 2026, VERAXA Biotech AG completed its business combination with Voyager Acquisition Corp. and listed on the NASDAQ Stock Market under the ticker symbols “VRXA” and “VRXAW”. Through this transaction, VERAXA strengthened its financial position, including through a USD 27.5 million senior secured note financing and a share purchase agreement for up to USD 50 million. The proceeds will be used to further advance VERAXA‘s oncology pipeline based on its proprietary BiTAC platform, supporting progress towards clinical development and industry partnerships.